Stephan Oehen
Fondateur chez Priothera Ltd.
Profil
Stephan Oehen is the founder of Priothera Ltd.
and Priothera SAS, both founded in 2020, where he holds the title of Chief Operating Officer.
He is also the founder of Investinswitzerland.
Currently, he is the owner of Oehen Pr.
In the past, he worked as the Deputy Chairman-Supervisory Board at Powerland AG and as the Managing Director at Grayling Schweiz AG from 2011 to 2013.
Postes actifs de Stephan Oehen
| Sociétés | Poste | Début |
|---|---|---|
| Oehen Pr | Corporate Officer/Principal | - |
Priothera SAS
 Priothera SAS BiotechnologyHealth Technology Part of Priothera Ltd., Priothera SAS is a French company dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of both allogeneic hematopoietic stem cell transplantation (HSCT) and CAR-T cell therapy. The company is based in Saint-Louis, France. Priothera is leading the way in developing Mocravimod, a S1P receptor modulator as an adjunctive and maintenance immune therapy to allo-HSCT and to CAR-T. Mocravimod has the potential to reduce the occurrence of (acute) GVHD without suppressing T cell function, thus GVL is maintained. Priothera is developing Mocravimod (KRP203) to significantly improve the clinical outcome of allo-HSCT and CAR-T therapy. The company was founded in 2020 by Philippe Lievre, Florent Gros, Brice R. Suire, Stephan Oehen, Simone Seiter. Florent Gros has been the CEO since 2020. | Fondateur | 30/09/2020 |
Priothera Ltd.
 Priothera Ltd. BiotechnologyHealth Technology Priothera Ltd. engages in the development of orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company was founded by Florent Gros, Shaval Patel, and Brice Suire in 2020 and is headquartered in Dublin, Ireland. | Fondateur | 01/01/2020 |
Anciens postes connus de Stephan Oehen
| Sociétés | Poste | Fin |
|---|---|---|
| Grayling Schweiz AG | Directeur Général | 01/01/2013 |
| Investinswitzerland | Fondateur | - |
| POWERLAND AG | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Powerland AG
 Powerland AG Consumer SundriesConsumer Non-Durables Powerland AG engages in the design, production, marketing and sale of bags and other textile and leather products. The company was founded in 2003 and is headquartered in Frankfurt, Germany. | Consumer Non-Durables |
| Oehen Pr | |
| Investinswitzerland | |
| Grayling Schweiz AG | |
Priothera SAS
Priothera SAS BiotechnologyHealth Technology Part of Priothera Ltd., Priothera SAS is a French company dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of both allogeneic hematopoietic stem cell transplantation (HSCT) and CAR-T cell therapy. The company is based in Saint-Louis, France. Priothera is leading the way in developing Mocravimod, a S1P receptor modulator as an adjunctive and maintenance immune therapy to allo-HSCT and to CAR-T. Mocravimod has the potential to reduce the occurrence of (acute) GVHD without suppressing T cell function, thus GVL is maintained. Priothera is developing Mocravimod (KRP203) to significantly improve the clinical outcome of allo-HSCT and CAR-T therapy. The company was founded in 2020 by Philippe Lievre, Florent Gros, Brice R. Suire, Stephan Oehen, Simone Seiter. Florent Gros has been the CEO since 2020. | Health Technology |
Priothera Ltd.
Priothera Ltd. BiotechnologyHealth Technology Priothera Ltd. engages in the development of orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company was founded by Florent Gros, Shaval Patel, and Brice Suire in 2020 and is headquartered in Dublin, Ireland. | Health Technology |
